Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
作者： Wen-Kai Weng , Ronald Levy
关键词:
摘要: Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin’s lymphoma, mechanism its antitumor effect not clear. One potential action involves antibody-dependent cellular cytotoxicity (ADCC). Two aspects ADCC influence effectiveness this process: susceptibility tumor cells and activation effector via their immunoglobulin G fragment C receptors (FcγRs). Several FcγR polymorphisms have been identified that may affect killing function natural killer macrophages. Patients Methods: The pretreatment from 43 patients with follicular lymphoma were tested for intrinsic to rituximab-mediated ADCC. In addition, FcγRIIIa (CD16) FcγRIIa (CD32) determined an expanded group 87 patients. results then correlated clinical outcome these Results: No difference was found between tumors who clinica...
jco.org参考文章(30)
D. R. Anderson, A. Grillo-López, C. Varns, K. S. Chambers, N. Hanna, TARGETED ANTI-CANCER THERAPY USING RITUXIMAB, A CHIMAERIC ANTI-CD20 ANTIBODY (IDEC-C2B8) IN THE TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA Biochemical Society Transactions. ,vol. 25, pp. 705- 708 ,(1997) , 10.1042/BST0250705
Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Manuela Lazzari, Gian-Maria Borleri, Sergio Bernasconi, Francesco Tedesco, Alessandro Rambaldi, Martino Introna, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood. ,vol. 95, pp. 3900- 3908 ,(2000) , 10.1182/BLOOD.V95.12.3900
Thomas Lehrnbecher, Charles B. Foster, Shaoxian Zhu, Susan F. Leitman, Lynn R. Goldin, Konrad Huppi, Stephen J. Chanock, Variant Genotypes of the Low-Affinity Fcγ Receptors in Two Control Populations and a Review of Low-Affinity Fcγ Receptor Polymorphisms in Control and Disease Populations Blood. ,vol. 94, pp. 4220- 4232 ,(1999) , 10.1182/BLOOD.V94.12.4220
R F Graziano, M W Fanger, Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. Journal of Immunology. ,vol. 139, pp. 3536- 3541 ,(1987)
Robert L Shields, Angela K Namenuk, Kyu Hong, Y Gloria Meng, Julie Rae, John Briggs, Dong Xie, Jadine Lai, Andrew Stadlen, Betty Li, Judith A Fox, Leonard G Presta, None, High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR Journal of Biological Chemistry. ,vol. 276, pp. 6591- 6604 ,(2001) , 10.1074/JBC.M009483200
Xiao-Ming Jiang, Gow Arepally, Mortimer Poncz, Steven E. McKenzie, Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). Journal of Immunological Methods. ,vol. 199, pp. 55- 59 ,(1996) , 10.1016/S0022-1759(96)00164-0
B. A. Vance, P. M. Guyre, T. W. J. Huizinga, K. Wardwell, Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. Journal of Immunology. ,vol. 151, pp. 6429- 6439 ,(1993)
Bruce D. Cheson, Sandra J. Horning, Bertr Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, T. Andrew Lister, Julie Vose, Antonio Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald Castellino, Nancy L. Harris, James O. Armitage, William Carter, Richard Hoppe, George P. Canellos, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Journal of Clinical Oncology. ,vol. 17, pp. 1244- 1244 ,(1999) , 10.1200/JCO.1999.17.4.1244
Chieko Kyogoku, Hilde M. Dijstelbloem, Naoyuki Tsuchiya, Yoko Hatta, Hitoshi Kato, Akihiro Yamaguchi, Toru Fukazawa, Marc D. Jansen, Hiroshi Hashimoto, Jan G. J. van de Winkel, Cees G. M. Kallenberg, Katsushi Tokunaga, Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis & Rheumatism. ,vol. 46, pp. 1242- 1254 ,(2002) , 10.1002/ART.10257
M. V. Dhodapkar, J. Krasovsky, K. Olson, T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 13009- 13013 ,(2002) , 10.1073/PNAS.202491499